We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Those in the pharmaceutical and biologics industry should be aware of recent changes to reporting requirements and deadlines under the Patented Medicines Regulations that came into force on March 6, 2008
The Federal Court of Appeal recently confirmed that patent settlement agreements may be subject to the provisions of the Competition Act; however, "something more" than a mere assertion of patent rights is required to amount to conspiracy under the Act
